Clinical Trials
5 trialsNCT04079738 2023-09-13
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02582359 2022-08-24
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Massachusetts General Hospital
Phase 1 Completed
NCT02030405 2019-04-05
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT02070458 2018-12-13
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02302846 2018-10-03
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
M.D. Anderson Cancer Center
Phase 2 Terminated